GIM
JAZZ icon

Granahan Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Granahan Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,631
Closed -$3.05M – 228
2017
Q2 		$3.05M Buy
19,631
+14,813
+307% +$2.27M 0.28% 110
2017
Q1 		$699K Buy
+4,818
New +$628K 0.07% 159

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Granahan Investment Management's JAZZ Position: Q3 2017 in Review

Granahan Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 19,631 shares — an estimated $3.05M sold.

Granahan Investment Management first reported a position in JAZZ in Q1 2017 and held it in 2 quarters. The position peaked at $3.05M in Q2 2017. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Granahan Investment Management reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Granahan Investment Management sold 19,631 Jazz Pharmaceuticals shares in Q3 2017, an estimated $3.05M.
  • Granahan Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Granahan Investment Management's Jazz Pharmaceuticals position peaked at $3.05M in Q2 2017.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Granahan Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.